The choice of delivery platform for inhaled drug products is contingent on API-related factors, as well as the development stage of the product.
Tim Gardner
Advertisement
Tim Gardner is director, manufacturing and NPI, Vectura.
Articles by Tim Gardner
Advertisement
Latest Updated Articles
Integrated Approach Facilitates Inhalation Drug DevelopmentPublished: August 1st 2021 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CNPV Deep Dive: Perspectives on Accelerated FDA Review From the C-Suite to the Manufacturing Floor
2
Is Pharma Solving the Right Problem with its Data Transformation Efforts?
3
De-risking Biologic Development: Engineering Flexibility from Early Development to Launch
4
Multi-Compendial Compliance for Pharmaceutical Excipients–Part 1: A Practical Application of Specification Equivalence
5